(Bloomberg) -- The list of Intel Corp.’s annual supplier award winners tends to read like a who’s-who of the semiconductor industry’s biggest names. This year, it included a little-known Japanese company whose machines have become indispensable in the race to improve semiconductors and whose stock has been rocketing up as a result.Lasertec Corp. is the world’s only maker of testing machines required to verify chip designs for the nascent extreme ultraviolet lithography (or EUV) method of chipmaking. In 2017, Lasertec solved a key piece of the EUV puzzle when it created a machine that can inspect blank EUV masks for internal flaws. Last September, it cleared another milestone by unveiling equipment that can do the same for stencils with chip designs already printed on them. This March, Intel gave the tiny Yokohama-based company an award for innovation, its first after decades of doing business together.“That’s a major milestone for us,” Lasertec...
U.S. biotech company Regeneron Pharmaceuticals, Inc (REGN) said on Monday that it will repurchase $5 billion of common stock held by France’s Sanofi.The biotech firm said that the offering will have no impact on its ongoing collaboration with Sanofi formed in 2003. Regeneron will fund the purchase with a combination of $3.5 billion of cash on hand and $1.5 billion of fully-committed bridge financing from Goldman Sachs Bank USA.“Sanofi and Regeneron’s collaboration has been one of the most productive in the industry, creating significant value for both companies but more importantly, resulting in five important medicines for patients,” said Sanofi CEO Paul Hudson.“The decision to divest our holdings is consistent with our efforts to enhance value creation for our shareholders.”The French drugmaker, which owns about 23.2 million of Regeneron shares, or a 20.6% stake intends to sell about 12.8 million shares in a public secondary offering. Sanofi will grant the underwriters a 30-day option to purchase an additional...